首页> 外文OA文献 >Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment

【2h】

Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment

机译：治疗前对晚期小细胞肺癌或非小细胞肺癌患者的血清基质金属蛋白酶9（MMP-9）和基质金属蛋白酶1组织抑制剂（TIMP-1）的测定

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Jumper Cynthia; Cobos Everardo; Lox Charles;
展开▼
作者单位

展开▼
年度 2004
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. [J] . Jumper C, Cobos E, Lox C Respiratory medicine . 2004,第2期

机译：治疗前对晚期小细胞肺癌或非小细胞肺癌患者的血清基质金属蛋白酶9（MMP-9）和基质金属蛋白酶1组织抑制剂（TIMP-1）的测定。
2. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients. [J] . Mroczko B, Groblewska M, Lukaszewicz Zajac M Clinical chemistry and laboratory medicine: CCLM . 2009,第9期

机译：胃癌患者的血清和血浆基质金属蛋白酶9（MMP-9）和基质金属蛋白酶1组织抑制剂（TIMP-1）的预处理水平。
3. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. [J] . Mroczko B, Lukaszewicz Zajac M, Wereszczynska Siemiatkowska U Pancreas . 2009,第6期

机译：胰腺癌患者血清基质金属蛋白酶9及其抑制剂（金属蛋白酶-1的组织抑制剂）的测定的临床意义：金属蛋白酶9是独立的预后因素。
4. Evaluation of Matrix Metalloproteinase-9 (MMP-9) and its tissue inhibitor of metalloproteinase-1 (Timp-1) in patients with coronary syndromes after percutaneous intervention(PCI) [C] . Revnic F., Revnic C.R., Nica A., International Congress on Coronary Artery Disease . 2011

机译：经皮干预后冠状动脉综合征患者中基质金属蛋白酶-9（MMP-9）及其组织抑制剂及其组织抑制剂（PCI）
5. Symptoms Leading to Nutritional Risk in Advanced Non-Small Cell Lung Cancer Patients: The Importance of Nutritional Screening in the Advanced Lung Cancer Population [D] . Swinton, Nelda. 2009

机译：导致晚期非小细胞肺癌患者营养风险的症状：在晚期肺癌人群中进行营养筛查的重要性
6. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients [O] . Barbara Mroczko, Magdalena Groblewska, Bogna Okulczyk, -1

机译：基质金属蛋白酶9（MMP-9）和基质金属蛋白酶1抑制剂（TIMP-1）测定对大肠腺瘤和癌症患者血清的诊断价值。
7. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients [O] . Mroczko, Barbara, Groblewska, Magdalena, Łukaszewicz-Zając, Marta, 2009

机译：胃癌患者血清和血浆基质金属蛋白酶9（mmp-9）和基质金属蛋白酶组织抑制因子1（TImp-1）的预处理

Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment

著录项

引文网络

相似文献

相关主题

期刊订阅